Your session is about to expire
← Back to Search
Y-90 Radioembolization for Liver Cancer
Study Summary
This trial is testing whether a treatment called Y-90 TARE can help control tumors on the right side of the liver, and if it can induce hypertrophy (growth) of the left liver as part of a planned hepatectomy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have symptoms from colon or rectal cancer and do not have an ostomy.I am mentally capable and willing to sign a consent form.My surgeon says I am fit for surgery.I have no medical reasons preventing me from having liver surgery.I need a procedure to prepare my liver for a major surgery aimed at curing me.I have cancer outside the liver that cannot be treated with the intent to cure, except for treatable primary tumor and lung metastases.I have significant difficulty with my daily activities due to my health.My cancer has worsened on scans or blood tests after 4 chemotherapy cycles, making surgery not an option.My colorectal cancer has spread to my liver, but surgery might still be possible.My liver's future remaining portion is expected to be less than 20% before treatment.I have portal hypertension or cirrhosis.I have completed at least four cycles or two months of chemotherapy.
- Group 1: Yttrium-90
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the recruitment period for this experiment ongoing?
"Affirmative. Clinicaltrials.gov has data that corroborates this trial is actively in search of participants, with the initial posting taking place on November 16th 2022 and the most recent update occurring one day later. The investigation requires 50 individuals to be drawn from a single medical centre."
What is the total enrolment capacity of this clinical trial?
"Affirmative. The clinical trial is indeed recruiting, as evidenced by the information found on clinicaltrials.gov - it was initially posted on November 16th and last amended on the 17th of that month. A total of 50 individuals are sought to participate at a single location."
Can Yttrium-90 (Y-90) resin microspheres be administered without any risk to health?
"Yttrium-90 (Y-90) resin microspheres has not been clinically evaluated a great deal, so its safety rating is 1 on our scale. This Phase 1 trial will provide data to support both efficacy and safety."
Share this study with friends
Copy Link
Messenger